All In Biotech

Drug Trial Radar · NCT05394116

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

63

Actual

Start

Nov 21, 2022

Primary completion

Jul 17, 2025

Study completion Feb 27, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • GaretosmabDrug

    Garetosmab is supplied as a liquid drug product and will be administered IV.

  • PlaceboDrug

    Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of New Heterotopic Ossification (HO) LesionsTime frame: Week 56
  2. Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)Time frame: Baseline up to Week 56 [to include participants who discontinued earlier]

Locations

22 sites in 18 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA) Medical Center

    Los Angeles, California

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Universidad de Concepcion

    Concepción, Biobio, Chile

  • Tongji Hospital of Tongji University

    Shanghai, China

  • Clinica Universidad de La Sabana

    Chía, Cundinamarca, Colombia

  • HUS Children and Adolescents Park Hospital Clinical Trial Unit

    Helsinki, Stenbäckinkatu 11, Finland

  • Hôpital Lapeyronie

    Montpellier, France

  • Hopital Lariboisiere

    Paris, France

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • IRCCS Istituto Giannina Gaslini

    Genoa, Italy

  • Kyushu University Hospital

    Fukuoka, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Oita University Hospital

    Yufu, Oita Prefecture, Japan

  • Hospital Kuala Lampur

    Kuala Lumpur, Malaysia

  • Amsterdam University Medical Center

    Amsterdam, North Holland, Netherlands

  • Szpital Centrum Medyczne Medyk

    Rzeszów, Podkarpackie Voivodeship, Poland

  • University of Cape Town

    Rondebosch, Cape Town, South Africa

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Royal National Orthropaedic Hospital NHS Trust

    Middlesex, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.